Ysios Capital is a Spanish venture capital firm that focuses on investing in early and development-stage life sciences companies, particularly those developing novel drugs across diverse modalities and therapeutic areas. Their strategy involves supporting companies through preclinical and clinical development, with a core emphasis on late preclinical and early clinical projects, and taking an active, hands-on role in their portfolio companies.
83% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (50% of deals). Average disclosed round size is $85.5M (across 5 rounds with reported amounts).
Portfolio
6
Fund Size
$500M
Top Stage
Series B
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 SpliceBio | Series B | $135M | Jun 2025 |
 Adcendo ApS | Series B | $135M | Nov 2024 |
 Tagworks Pharmaceuticals | Series A | $65M | Jun 2023 |
| SpliceBio | Series A | $50M | Feb 2022 |
 CorWave | Series B | $42.5M | Jan 2021 |
 Vivet Therapeutics | Series A | — | May 2017 |
Top Co-Investors
Novartis Venture Fund4 shared
Gilde Healthcare4 shared
NEA (New Enterprise Associates)3 shared
Novo Holdings2 shared
Roche Venture Fund2 shared
HealthCap2 shared
UCB2 shared
Asabys2 shared
Bpifrance1 shared
Seventure Partners1 shared
Sofinnova Partners1 shared
Columbus Venture Partners1 shared
Kurma Partners1 shared
Lightstone Ventures1 shared
OrbiMed1 shared
Surveyor Capital1 shared
Logos Capital1 shared
RA Capital Management1 shared
Last updated: 21 April 2026